Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls

Mei, Qixiang; Huang, Chen; Luo, Shengzheng; Zhang, Xuemei; Zeng, Yue; Lu, Yingying

doi:10.1016/j.pan.2018.03.005

Cited by 79 publications

(69 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies on the microbiome of PC patients have been focused on saliva [8], duodenal mucosa [9] and feces [10], and the results have shown dramatically different saliva, duodenal mucosa and fecal microbiota structure in PC patients compared with controls. However, the characteristics of the tongue coating microbiota of patients with PC have not yet been clearly defined.…”

Section: Introductionmentioning

confidence: 99%

Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls

Lü

Ren

et al. 2019

Journal of Oral Microbiology

103

View full text Add to dashboard Cite

Background: The microbiota plays a critical role in the process of human carcinogenesis. Pancreatic head carcinoma (PHC)-associated tongue coating microbiome dysbiosis has not yet been clearly defined.Objective: Our aim is to reveal the bacterial composition shifts in the microbiota of the tongue coat of PHC patients.Design: The tongue coating microbiota was analyzed in 30 PHC patients and 25 healthy controls using 16S rRNA gene sequencing technology.Results: The microbiome diversity of the tongue coat in PHC patients was significantly increased, as shown by the Shannon, Simpson, inverse Simpson, Obs and incidence-based coverage estimators. Principal component analysis revealed that PHC patients were colonized by remarkably different tongue coating microbiota than healthy controls and liver cancer patients. Linear discriminant analysis effect size revealed that Leptotrichia, Fusobacterium,Rothia, Actinomyces, Corynebacterium, Atopobium, Peptostreptococcus, Catonella, Oribacterium, Filifactor, Campylobacter, Moraxella and Tannerella were overrepresented in the tongue coating of PHC patients, and Haemophilus, Porphyromonas and Paraprevotella were enriched in the tongue coating microbiota of healthy controls. Strikingly, Haemophilus, Porphyromonas, Leptotrichia and Fusobacterium could distinguish PHC patients from healthy subjects, and Streptococcus and SR1 could distinguish PHC patients from liver cancer patients. Conclusions: These findings identified the microbiota dysbiosis of the tongue coat in PHC patients, and provide insight into the association between the human microbiome and pancreatic cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls

Lü

Ren

et al. 2019

Journal of Oral Microbiology

103

View full text Add to dashboard Cite

show abstract

“…The association of Tyzzerella 4 from the Lachnospiraceae family with CRC can be due to its increased occurrence in patients with higher cardiovascular risk (CVR) factor scores [84], that are associated also with CRC [85]. Presence of Massilia in CRC patients was also never described previously, but it was detected in patients with pancreatic cancer [86].…”

Section: Tumour Crc Microbial Subtypesmentioning

confidence: 91%

Tumour Microbiome-Based Subtypes of Colorectal Cancer Correlate with Clinical Variables

Zwinsová¹,

Петров²,

Hrivňáková³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundLong-term dysbiosis of the gut microbiome has a significant impact on the development, progression and the aggressiveness of colorectal cancer (CRC) and may explain part of the observed heterogeneity of the disease from phenotypic, prognostic and response to treatment perspectives. Although the shifts in gut microbiome in the normal-adenoma-carcinoma sequence have been described, the landscape of microbiome within CRC and its associations with clinical variables remain under-explored. ResultsWe performed 16S rRNA gene sequencing of paired tumour tissue, adjacent visually-normal mucosa and stool swabs of N=186 patients with stage 0-IV CRC to describe the tumour microbiome and its association with clinical variable and to derive tumour microbial subtypes.We identified new genera never previously associated with CRC tumour mucosa (Flavonifractor, Haemophilus, Howardella, Pseudomonas, Sutterella, Treponema 2) or CRC (Actinobacillus, Aggregatibacter, Bergeyella, Phocaeiola, Defluviitaleaceae UCG-011, Massilia, Tyzzerella 4). The bacteria residing on tumour-mucosa were dominated by genera belonging to (potential) oral pathogens. Based on tumour microbial profiles, we stratified CRC patients into three subtypes. The subtypes were significantly associated with prognostic factors such as tumor grade, primary tumour sidedness and TNM staging, with one subtype enriched in tumours with poor prognosis. Further, we inspected the associations of microbiome with clinical variables in a subtype-agnostic setting. The primary tumour-associated clinical variables predominantly correlated with tumour mucosal microbiome, while the presence of local and distant metastases was mostly associated with the stool microbiome.ConclusionsUnderstanding the interactions of the bacteria residing on tumour mucosa within different CRC tumour microbiome subtypes will help to better understand the underlying biological background of the heterogeneity of this disease. Indeed, the tumour microbiome is a possible source of additional integrative markers of CRC patients’ survival and prognosis. We found that CRC microbiome is strongly correlated with clinical variables, but these associations are dependent on the microbial environment (tumour mucosa, normal mucosa, stool). Our study thus identifies limitations of the usage of microbiome composition as marker of CRC progression, suggesting the need of combining several sampling sites (e.g. stool and tumour swabs).

show abstract

“…The microbiota of the duodenal mucosa in PDAC patients and healthy controls shared similar species in one study. However, duodenal samples of PDAC were characterized by enrichment with, for example, Acinetobacter, Aquabacterium, Oceanobacillus and Rahnella [17]. Limitations exist in determining whether microbiota alterations contribute to tumor progression, and whether the altered host microbiota is merely a concomitant manifestation remains elusive.…”

Section: Therapeutic Dilemma Of Pancreatic Cancermentioning

confidence: 99%

Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy

et al. 2020

View full text Add to dashboard Cite

Pancreatic cancer remains one of the leading causes of cancer-related death worldwide and has a poor prognosis. Current treatment relies on surgical resection and adjuvant therapies. The gut microbiota plays important roles in metabolism and immunomodulation. Accumulating evidence has implied that the gut microbiota is involved in the metabolism of chemotherapeutic drugs and the tumor microenvironment (TME), which could affect the efficacy of both conventional chemotherapy and immunotherapy for pancreatic cancer. Herein, we comprehensively reviewed the history and highlights of the interactions among pancreatic cancer, the gut microbiota and therapeutic efficacy and showed the promising future of manipulating the gut microbiota to improve clinical outcomes of pancreatic cancer.

show abstract

Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls

Cited by 79 publications

References 29 publications

Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls

Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls

Tumour Microbiome-Based Subtypes of Colorectal Cancer Correlate with Clinical Variables

Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy

Contact Info

Product

Resources

About